Production (Stage)
MoonLake Immunotherapeutics
MLTX
$46.88
-$1.95-3.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 19.58% | 25.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.23% | 15.00% | |||
| Operating Income | 4.23% | -15.00% | |||
| Income Before Tax | 12.83% | -28.68% | |||
| Income Tax Expenses | 272.26% | -55.37% | |||
| Earnings from Continuing Operations | 12.58% | -28.47% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -22.27% | 9.27% | |||
| Net Income | 12.41% | -28.86% | |||
| EBIT | 4.23% | -15.00% | |||
| EBITDA | 2.43% | -12.07% | |||
| EPS Basic | 12.64% | -28.51% | |||
| Normalized Basic EPS | 12.80% | -28.98% | |||
| EPS Diluted | 12.64% | -28.51% | |||
| Normalized Diluted EPS | 12.80% | -28.98% | |||
| Average Basic Shares Outstanding | 0.26% | 0.28% | |||
| Average Diluted Shares Outstanding | 0.26% | 0.28% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||